Fig. 2
Bone marrow edema (BME) scores in patients with early arthritis (n = 589) with different combinations of anti-citrullinated protein antibodies (ACPA), rheumatoid factor (RF) and anti-carbamylated protein antibodies (anti-CarP). Horizontal lines represent median. Whiskers show the 10th–90th percentile. Dots represent outliers. ACPA+, RF+, anti-CarP- patients vs. ACPA-, RF-, anti-CarP- patients, p < 0.001; ACPA+, RF+, anti-CarP+ patients vs. ACPA-, RF-, anti-CarP- patients, p < 0.001. ACPA-, RF-, anti-CarP- patients, n = 353; ACPA-, RF+, anti-CarP- patients, n = 68; ACPA+, RF-, anti-CarP- patients, n = 15; ACPA+, RF+, anti-CarP- patients, n = 48; ACPA-, RF-, anti-CarP+ patients, n = 11; ACPA-, RF+, anti-CarP+ patients, n = 3; ACPA+, RF-, anti-CarP+ patients, n = 5; ACPA+, RF+, anti-CarP+ patients, n = 69. Total score: sum of BME scores in metacarpophalangeal, wrist, and metatarsophalangeal joints. *Significant difference (p < 0.05) between subgroups